share_log

Market-Moving News for September 16th

Benzinga ·  Sep 16, 2024 05:08

NCNA: 282% | NuCana Presented Final Data From Phase 2 Nutide:701 Study At ESMO Congress On NUC-7738 In Combination With Pembrolizumab For Patients With Metastatic Melanoma Who Were Refractory To Or Had Relapsed On Prior PD-1 Inhibitor Therapy

ZNTL: 49% | Zentalis Pharmaceuticals shares are trading higher after the company announced that the FDA lifted the partial clinical hold on studies of azenosertib and remains on track to meet all previously disclosed data guidance for the remainder of 2024.

ITOS: -16% | iTeos Therapeutics shares are trading lower. The company announced follow-up interim data from GALAXIES Lung-201,

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment